PortalPublikationenPrognostic impact of secondary prevention after coronary art...

Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial

Standard

Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. / Heer, Tobias; von Scheidt, Moritz; Boening, Andreas; Heyken, Clarissa; Gusmini, Friederike; de Waha, Antoinette; Kuna, Constantin; Fach, Andreas; Grothusen, Christina; Oberhoffer, Martin; Knosalla, Christoph; Walther, Thomas; Danner, Bernhard C; Misfeld, Martin; Wimmer-Greinecker, Gerhard; Siepe, Matthias; Grubitzsch, Herko; Joost, Alexander; Schaefer, Andreas; Conradi, Lenard; Cremer, Jochen; Hamm, Christian; Lange, Rüdiger; Radke, Peter W; Schulz, Rainer; Laufer, Günther; Grieshaber, Philippe; Attmann, Tim; Schmoeckel, Michael; Meyer, Alexander; Ziegelhöffer, Tibor; Hambrecht, Rainer; Sandner, Sigrid E; Kastrati, Adnan; Schunkert, Heribert; Zeymer, Uwe.

in: EUR J CARDIO-THORAC, Jahrgang 62, Nr. 3, ezac048, 03.08.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Heer, T, von Scheidt, M, Boening, A, Heyken, C, Gusmini, F, de Waha, A, Kuna, C, Fach, A, Grothusen, C, Oberhoffer, M, Knosalla, C, Walther, T, Danner, BC, Misfeld, M, Wimmer-Greinecker, G, Siepe, M, Grubitzsch, H, Joost, A, Schaefer, A, Conradi, L, Cremer, J, Hamm, C, Lange, R, Radke, PW, Schulz, R, Laufer, G, Grieshaber, P, Attmann, T, Schmoeckel, M, Meyer, A, Ziegelhöffer, T, Hambrecht, R, Sandner, SE, Kastrati, A, Schunkert, H & Zeymer, U 2022, 'Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial', EUR J CARDIO-THORAC, Jg. 62, Nr. 3, ezac048. https://doi.org/10.1093/ejcts/ezac048

APA

Heer, T., von Scheidt, M., Boening, A., Heyken, C., Gusmini, F., de Waha, A., Kuna, C., Fach, A., Grothusen, C., Oberhoffer, M., Knosalla, C., Walther, T., Danner, B. C., Misfeld, M., Wimmer-Greinecker, G., Siepe, M., Grubitzsch, H., Joost, A., Schaefer, A., ... Zeymer, U. (2022). Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. EUR J CARDIO-THORAC, 62(3), [ezac048]. https://doi.org/10.1093/ejcts/ezac048

Vancouver

Heer T, von Scheidt M, Boening A, Heyken C, Gusmini F, de Waha A et al. Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial. EUR J CARDIO-THORAC. 2022 Aug 3;62(3). ezac048. https://doi.org/10.1093/ejcts/ezac048

Bibtex

@article{5d9e840df28c4167ac333fee1419d302,
title = "Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial",
abstract = "OBJECTIVES: There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG.METHODS: Data were taken from the randomized 'Ticagrelor in CABG' trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing.RESULTS: Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05-0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01-0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39-0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39-0.78), P < 0.001]; normal renal function [HR 0.99 (0.98-0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02-4.18), P = 0.045].CONCLUSIONS: Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.",
keywords = "Coronary Artery Bypass/adverse effects, Coronary Artery Disease/surgery, Humans, Prognosis, Secondary Prevention, Ticagrelor, Treatment Outcome",
author = "Tobias Heer and {von Scheidt}, Moritz and Andreas Boening and Clarissa Heyken and Friederike Gusmini and {de Waha}, Antoinette and Constantin Kuna and Andreas Fach and Christina Grothusen and Martin Oberhoffer and Christoph Knosalla and Thomas Walther and Danner, {Bernhard C} and Martin Misfeld and Gerhard Wimmer-Greinecker and Matthias Siepe and Herko Grubitzsch and Alexander Joost and Andreas Schaefer and Lenard Conradi and Jochen Cremer and Christian Hamm and R{\"u}diger Lange and Radke, {Peter W} and Rainer Schulz and G{\"u}nther Laufer and Philippe Grieshaber and Tim Attmann and Michael Schmoeckel and Alexander Meyer and Tibor Ziegelh{\"o}ffer and Rainer Hambrecht and Sandner, {Sigrid E} and Adnan Kastrati and Heribert Schunkert and Uwe Zeymer",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.",
year = "2022",
month = aug,
day = "3",
doi = "10.1093/ejcts/ezac048",
language = "English",
volume = "62",
journal = "EUR J CARDIO-THORAC",
issn = "1010-7940",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Prognostic impact of secondary prevention after coronary artery bypass grafting-insights from the TiCAB trial

AU - Heer, Tobias

AU - von Scheidt, Moritz

AU - Boening, Andreas

AU - Heyken, Clarissa

AU - Gusmini, Friederike

AU - de Waha, Antoinette

AU - Kuna, Constantin

AU - Fach, Andreas

AU - Grothusen, Christina

AU - Oberhoffer, Martin

AU - Knosalla, Christoph

AU - Walther, Thomas

AU - Danner, Bernhard C

AU - Misfeld, Martin

AU - Wimmer-Greinecker, Gerhard

AU - Siepe, Matthias

AU - Grubitzsch, Herko

AU - Joost, Alexander

AU - Schaefer, Andreas

AU - Conradi, Lenard

AU - Cremer, Jochen

AU - Hamm, Christian

AU - Lange, Rüdiger

AU - Radke, Peter W

AU - Schulz, Rainer

AU - Laufer, Günther

AU - Grieshaber, Philippe

AU - Attmann, Tim

AU - Schmoeckel, Michael

AU - Meyer, Alexander

AU - Ziegelhöffer, Tibor

AU - Hambrecht, Rainer

AU - Sandner, Sigrid E

AU - Kastrati, Adnan

AU - Schunkert, Heribert

AU - Zeymer, Uwe

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

PY - 2022/8/3

Y1 - 2022/8/3

N2 - OBJECTIVES: There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG.METHODS: Data were taken from the randomized 'Ticagrelor in CABG' trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing.RESULTS: Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05-0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01-0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39-0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39-0.78), P < 0.001]; normal renal function [HR 0.99 (0.98-0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02-4.18), P = 0.045].CONCLUSIONS: Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.

AB - OBJECTIVES: There are disparities in the adherence to guideline-recommended therapies after coronary artery bypass graft (CABG). We therefore sought to evaluate the effect of guideline-adherent medical secondary prevention on 1-year outcome after CABG.METHODS: Data were taken from the randomized 'Ticagrelor in CABG' trial. From April 2013 until April 2017, patients who underwent CABG were included. For the present analysis, we compared patients who were treated with optimal medical secondary prevention with those where 1 or more of the recommended medications were missing.RESULTS: Follow-up data at 12 months were available in 1807 patients. About half (54%) of them were treated with optimal secondary prevention. All-cause mortality [0.5% vs 3.5%, hazard ratio (HR) 0.14 (0.05-0.37), P < 0.01], cardiovascular mortality [0.1% vs 1.7%, HR 0.06 (0.01-0.46), P = 0.007] and major adverse events [6.5% vs 11.5%, HR 0.54 (0.39-0.74), P < 0.01] were significantly lower in the group with optimal secondary prevention. The multivariable model for the primary end point based on binary concordance to guideline recommended therapy identified 3 independent factors: adherence to guideline recommended therapy [HR 0.55 (0.39-0.78), P < 0.001]; normal renal function [HR 0.99 (0.98-0.99), P = 0.040]; and off-pump surgery [HR 2.06 (1.02-4.18), P = 0.045].CONCLUSIONS: Only every second patient receives optimal secondary prevention after CABG. Guideline adherent secondary prevention therapy is associated with lower mid-term mortality and less adverse cardiovascular events after 12 months.

KW - Coronary Artery Bypass/adverse effects

KW - Coronary Artery Disease/surgery

KW - Humans

KW - Prognosis

KW - Secondary Prevention

KW - Ticagrelor

KW - Treatment Outcome

U2 - 10.1093/ejcts/ezac048

DO - 10.1093/ejcts/ezac048

M3 - SCORING: Journal article

C2 - 35138350

VL - 62

JO - EUR J CARDIO-THORAC

JF - EUR J CARDIO-THORAC

SN - 1010-7940

IS - 3

M1 - ezac048

ER -